RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis
- 17 June 2004
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1704 (2), 49-57
- https://doi.org/10.1016/j.bbcan.2004.05.002
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Receptor Activator of Nuclear Factor κB Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe OsteolysisThe American Journal of Pathology, 2003
- Immunohistochemical study of receptor activator of nuclear factor kappa‐B ligand (RANK‐L) in human osteolytic bone tumorsJournal of Surgical Oncology, 2002
- Osteoprotegerin: a new therapeutic agent for the treatment of bone diseaseDrug Discovery Today, 2001
- Mechanisms of Tumor Metastasis to BoneCritical Reviews™ in Eukaryotic Gene Expression, 2000
- Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandNature, 1999
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Cancer and BoneEndocrine Reviews, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997
- Direct resorption of bone by human breast cancer cells in vitroNature, 1978